As the first first Novartis viral vector production facility in Europe, it significantly expands Novartis' research and ...

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive Giovanni Caforio as ...

Novartis has started the first phase of a programme that will make 15 of its essential medicines available in lower-income countries for just $1 per drug per month. The Novartis Access scheme ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established heart failure drug Entresto and multiple sclerosis drug Kesimpta.

We will listen to different communities with a learning mindset to do what we can to contribute to building a world that is safer and more inclusive. At Novartis, we celebrate life and recognize ...

Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...

FRANKFURT, Jan 31 (Reuters) - Novartis (NOVN.S), opens new tab on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer ...

The transaction, which is subject to customary closing conditions, is fully in line with Novartis’ growth strategy and therapeutic area focus, leveraging the company’s strength and expertise in the ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...